Antithrombotic Therapy for Peripheral Artery Disease
Authors:
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Cilostazol Reduces Angiographic Restenosis After Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol StudyCirculation, 2013
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Vorapaxar in the Secondary Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2012
- Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary SyndromesNew England Journal of Medicine, 2012
- Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health RegistryEuropean Heart Journal, 2009
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA TrialJACC, 2007
- Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double‐blind trialJournal of Internal Medicine, 2007
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996